
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
[ Fri, Feb 26th 2021 ]: WOPRAI
Difei Yang Maintained (SRPT) at Strong Buy with Increased Target to $160 on, Feb 26th, 2021


🞛 This publication is a summary or evaluation of another publication
Difei Yang of Mizuho, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $158 to $160 on, Feb 26th, 2021.
Difei has made no other calls on SRPT in the last 4 months.
There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 5 agree with Difei's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Joel Beatty of "Citigroup" Downgraded from Strong Buy to Hold and Held Target at $108 on, Tuesday, January 12th, 2021
- Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
- Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
- Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
- Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021
These are the ratings of the 3 analyists that currently disagree with Difei
- Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
- Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $125 on, Friday, January 8th, 2021